Drug intelligence / Profile preview

standard of care + colchicine + rosuvastatin

Development stage
Phase 4
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Oral
01

Overview

Combination regimen consisting of **standard of care therapies**, **colchicine**, and **rosuvastatin**. This combination has been primarily investigated in hospitalized patients with COVID-19 to assess whether adding colchicine (an anti-inflammatory) and rosuvastatin (a statin for lipid-lowering and cardiovascular protection) to usual hospital treatments could reduce progression to severe disease, thromboembolic events, or mortality. Colchicine works by inhibiting microtubule polymerization and decreasing neutrophil activation and chemotaxis (anti-inflammatory effect). Rosuvastatin is a hydrophilic HMG-CoA reductase inhibitor that lowers LDL cholesterol and exerts anti-inflammatory and endothelial-protective effects. The combination aims to leverage the anti-inflammatory and cardiovascular protective effects of both agents on top of standard therapies, which may include antivirals, corticosteroids, immunomodulators, and antithrombotics.

Other names
Colchicine/StatinRosuvastatin and Colchicine
02

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on standard of care + colchicine + rosuvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on standard of care + colchicine + rosuvastatin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call